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Abstract
OBJECTIVE: To study the protective effects of
Dongchongxiacao (Cordyceps) (DCXC) on con-
trast-induced nephropathy (CIN) in patients with
type 2 diabetes and renal insufficiency undergoing
coronary angiography.
METHODS: A total of 120 patients with type 2 dia-
betes whose estimated glomerular filtration rate
(eGFR) was ≤ 60 mL/min·1.73 m2, were divided ran-
domly into three groups, basic treatment group
(n = 41), standard DCXC therapy group (n = 39, 2-g
corbrin capsules, 3 times/d, 3 days before and after
angiography), and intensive DCXC therapy group
(n = 40, 3-g corbrin capsules, 3 times/d, 3 days be-
fore and after angiography). Serum creatinine (Scr)
and eGFR were assessed at the time of admission
to hospital, and on days 1, 2 and 3 after angiogra-
phy. Urine neutrophil-gelatinase-associated-lipo-
calin (NGAL), kidney injury molecule-1 (KIM-1) and
interleukin-18 (IL-18) were measured before angi-
ography and at day 1 after angiography for all pa-
tients. The primary end point was the prevalence of
CIN. The secondary end point was a 25% or greater
reduction in eGFR.
RESULTS: CIN occurred in 11 of 120 patients
(9.17 % ). The prevalence of CIN was lower in the
DCXC treatment groups than in the basic treatment
group (P < 0.05), with a more significant decrease
in the prevalence of CIN in the intensive DCXC ther-
apy group (P < 0.01). Compared with the basic
treatment group, a lower proportion of patients in
the DCXC treatment groups had an eGFR decrease
of 25% or greater (P < 0.05); patients with an eGFR
decrease of 25% or greater accounted for an even
lower proportion in the intensive DCXC therapy
group (P < 0.01). Within 1 day of the procedure,
urine levels of KIM-1, NGAL and IL-18 in patients in
the intensive DCXC therapy group were lower than
those in the basic treatment group and standard
therapy group (P < 0.05).
CONCLUSION: DCXC treatment may protect
against CIN in patients with type 2 diabetes and re-
nal insufficiency undergoing coronary angiogra-
phy, with intensive DCXC therapy being more effec-
tive.
© 2015 JTCM. All rights reserved.
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INTRODUCTION
The prevalence of contrast-induced nephropathy
(CIN) is rising due to the increased use of contrast me-
dia in percutaneous coronary intervention. CIN is an
adverse event that results in increased health resource
usage, prolongs hospital stay, and increases short- and
long-term mortality, even after adjustment for other
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co-morbidities. CIN has become the third leading
cause of hospital acquired acute renal failure.1,2 The risk
factors for CIN include chronic kidney disease, the vol-
ume of contrast agent, diabetes, advanced age, sex, gen-
der, congestive heart failure, anemia, and dehydration.3
The prevalence of CIN in patients with diabetes and
preserved renal function is only moderately increased
or even comparable with the healthy population; how-
ever patients with diabetes and renal insufficiency have
a significantly increased risk of CIN.4 Once CIN devel-
ops, hydration status optimization is the only proven
strategy to treat it, and no other adjunctive medical or
mechanical treatment specifically targets CIN. The
main goal for clinicians is to find preventative mea-
sures.5 There have been few clinical trials to evaluate
the role of traditional Chinese medicine in preventing
patients with diabetic nephropathy from developing
CIN. The objective of the present study was to evalu-
ate Dongchongxiacao (Cordyceps) (DCXC) as prophy-
laxis for the development of CIN in patients with type
2 diabetes and renal insufficiency undergoing coronary
angiography.
METHODS
Ethical approval of the study protocol
The study protocol was approved by the Ethics Com-
mittee of Tianjin Nankai Hospital (Tianjin, China).
All patients provided written informed consent prior
to inclusion in the study.
Study population
The present study was conducted at the Department of
Cardiology at Tianjin Nankai Hospital from October
2012 to January 2014. Patients with type 2 diabetes,
whose estimated glomerular filtration rate (eGFR)
was ≤ 60 mL/min/1.73 m2, were enrolled into the cur-
rent study. Patients > 18 years and < 80 years of age
met the inclusion criteria. Samples were selected using
a random number table. A total of 120 eligible patients
were divided randomly into three groups, basic treat-
ment group (n = 41), standard DCXC therapy group
(n = 39, 2-g corbrin capsules, 3 times/day, 3 days be-
fore and after angiography), and intensive DCXC ther-
apy group (n = 40, 3-g corbrin capsules, 3 times/d, 3
days before and after angiography). Type 2 diabetes
was defined as any of the following: fasting plasma glu-
cose level greater than 7.0 mmol/L or a random plasma
glucose level of 11.1 mmol/L or greater. Repeated mea-
surement of fasting or random plasma glucose levels on
subsequent days was used to confirm the diagnosis of
diabetes. The eGFR was calculated using the modifica-
tion of diet in renal disease (MDRD) equation.6 The
exclusion criteria included patients who were hyperpy-
rexic or allergic to iodine or who had one of the follow-
ing: tumors; severe heart failure; severe kidney failure;
severe liver failure; disorders of the immune system;
blood diseases.
Intervention
All patients were given intravenous isotonic saline
(0.9%) at a rate of approximately 1 mL/kg per hour
for 6 h before, and 12 h after, contrast exposure. All
patients received aspirin (100 mg/d was administered
indefinitely), clopidogrel (600 mg loading dose, fol-
lowed by 75 mg/d for at least 12 months), rosuvas-
tatin (10 mg/d), metoprolol (23.75 mg/d), benazepril
(10 mg/d), fondaparinux (2.5 mg/d for at least 5 days),
furosemide (20 mg/d). Patients in the DCXC groups
received corbrin capsules (Hangzhou Zhongmei Hua-
dong Pharmaceuticals, Hangzhou, China). The use
of aspirin (Bayer Pharmaceuticals, Beijing, China),
clopidogrel (Sanofi Pharmaceuticals, Hangzhou, Chi-
na), statins (Pfizer Pharmaceuticals, Shanghai, Chi-
na), beta-blocker (Astrazeneca Pharmaceuticals, Wuxi,
China), anticoagulation agents (Sanofi Pharmaceuti-
cals, Hangzhou, China), angiotensin converting en-
zyme inhibitors (Novartis Pharmaceuticals, Beijing,
China), and diuretics (Tianjin LiSheng Pharmaceuti-
cals, Tianjin, China), was left to the discretion of the
cardiologist according to clinical requirements or guide-
line recommendations. All procedures were undertak-
en with low-osmolarity non-ionic contrast media (Io-
pamidol, i.v.). The volume of contrast media used was
recorded for all patients during catheterization.
Outcome measures
Serum levels of triglycerides (TG), total cholesterol
(TC), high-density lipoprotein-cholesterol (HDL-C),
low-density lipoprotein-cholesterol (LDL-C), blood
glucose, and glycosylated hemoglobin, were measured
at the time of hospital admission. Serum creatinine
(Scr) and eGFR were measured at the time of hospital
admission and 1, 2 and 3 days after the procedure. The
concentration of urine neutrophil-gelatinase-associ-
ates-lipocalin (NGAL), kidney injury molecule-1
(KIM-1), and interleukin-18 (IL-18) in urine were de-
tected before and one day after the procedure for pa-
tients in three groups. The urine levels of NGAL,
IL-18 and KIM-1 were determined by enzyme-linked
immunosorbent assay (ELISA) in the clinical laborato-
ry of Tianjin Nankai Hospital.
Statistical analyses
Continuous variables and categorical variables are ex-
pressed as the mean ± standard deviation ( xˉ ± s)
and percentages, respectively. All samples were tested
to ascertain if they followed a normal distribution.
Categorical variables were compared using the χ2 test
or the Fishers exact test where appropriate. One-way
analysis of variance was applied for the analysis of
continuous variables among the three groups.
Two-tailed P values of P < 0.05 were considered sta-
tistically significant. Statistical analyses were per-
formed using SPSS 13.0 (SPSS Inc., Chicago, IL,
USA).
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RESULTS
Safety and adverse reaction evaluation
In the present study, no patients developed clinical re-
nal failure. No arrhythmias, blurred vision, palpita-
tions, or retention of urine were found in the DCXC
treatment groups or in the basic treatment group. Pa-
tients in the DCXC treatment groups and in the basic
treatment group had no adverse reactions during the
procedure.
Baseline clinical characteristics
A total of 120 eligible patients were randomized to the
basic treatment group (n = 41), standard DCXC thera-
py group (n = 39), and intensive DCXC therapy group
(n = 40). Baseline clinical and procedural characteris-
tics are listed in Table 1, Figure 1. There were no statis-
tically significant differences in these characteristics
among the three treatment groups (P > 0.05).
Changes in Scr and eGFR levels
The changes in Scr and eGFR levels are listed in Table
2. Scr levels were increased significantly in all groups af-
ter the procedure. The peak Scr value occurred at day 2
and then began to decrease. The intensive DCXC ther-
apy group tended to have a lower Scr level than the ba-
sic treatment group and standard DCXC therapy
group at day 2 after the procedure (P < 0.05). There
was no significant difference between the standard ther-
apy group and the basic treatment group (P > 0.05).
Scr levels were higher than baseline le vels at day 3, but
there was no significant difference among the three
groups (P > 0.05).
eGFR levels were decreased significantly in all groups
after the procedure. The eGFR levels were significantly
higher in the intensive DCXC therapy group than in
the basic treatment group and standard DCXC therapy
group at day 2 after the procedure (P < 0.05). There
was no significant difference between the standard ther-
Characteristics
Sex (male/female)
Age (years)
Age > 70 years [n (%)]
BMI (kg/m2)
Hypertension [n (%)]
Cholesterol (mmol/L)
Triglycerides (mmol/L)
HDL-C (mmol/L)
LDL-C (mmol/L)
Glycosylated hemoglobin (%)
Blood glucose (mmol/L)
VOCM (mL)
Hydration volume (mL)
LVEF (%)
Statins [n (%)]
Aspirin [n (%)]
Clopidogrel [n (%)]
Beta-blocker [n (%)]
Anticoagulation agents [n (%)]
Diuretics [n (%)]
ACEI [n (%)]
Basic treatment Group
(n = 41)
22/19
64.58±5.71
10 (24.39)
27.18±5.71
27 (65.85)
4.82±1.23
1.85±0.94
1.17±0.33
2.74±0.93
5.85±0.94
5.67±1.67
246.85±49.74
843.00±158.00
59.26±11.62
40 (97.56)
38 (92.68)
29 (70.73)
33 (80.49)
25(60.98)
22 (55.00)
31 (75.61)
Standard DCXC therapy
Group (n = 39)
23/16
63.94±4.26
8 (20.51)
26.92±6.23
26 (66.67)
4.75±1.71
1.78±0.87
1.18±0.29
2.82±0.40
6.18±0.87
5.31±1.76
248.87±48.69
872.00±137.00
58.73±11.85
39 (100.00)
35 (89.74)
27 (69.23)
31 (79.49)
23 (58.97)
21 (53.85)
29 (74.36)
Intensive DCXC therapy
Group (n = 40)
21/19
65.12±6.27
9 (22.50)
28.02±8.06
29 (72.50)
4.48±1.29
1.49±0.86
1.19±0.31
2.56±1.05
5.99±0.86
5.26±2.31
250.87±50.72
855.00±141.00
61.32±12.08
38 (95.00)
36 (90.00)
29 (72.50)
31 (77.50)
25 (62.50)
23 (57.50)
31 (77.50)
F/χ2
0.721
0.687
0.319
0.381
0.116
0.824
0.325
0.556
0.374
0.581
0.668
0.572
0.589
0.613
0.824
0.796
0.715
0.737
0.698
0.676
0.812
P
value
0.52
0.49
0.28
0.31
0.17
0.63
0.29
0.47
0.32
0.49
0.51
0.47
0.51
0.55
0.97
0.89
0.82
0.86
0.79
0.77
0.91
Notes: basic treatment group was received aspirin (100 mg/d was administered indefinitely), clopidogrel (600 mg loading dose, followed
by 75 mg/d for at least 12 months), rosuvastatin (10 mg/d), metoprolol (23.75 mg/d), benazepril (10 mg/d), fondaparinux (2.5 mg/d for
at least 5 days),furosemide (20 mg/d). Standard DCXC therapy group was treated with 2-g corbrin capsules, 3 times/day, 3 days before
and after angiography. Intensive DCXC therapy group was treated with 3-g corbrin capsules, 3 times/day, 3 days before and after angiogra-
phy. DCXC: Dongchongxiacao (Cordyceps); BMI: body mass index; LDL-C: low-density lipoprotein-cholesterol; HDL-C: high-density li-
poprotein-cholesterol; VOCM: volume of contrast medium; LVEF: left ventricular ejection fraction. ACEI: angiotensin converting en-
zyme inhibitors.
Table 1 Baseline clinical and procedural characteristics of study patients ( xˉ ± s)
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apy group and the basic treatment group (P > 0.05).
The eGFR levels were lower than baseline levels at day
3 in all groups, with no significant differences among
the three groups (P > 0.05).
Changes in urine KIM-1, NGAL and IL-18 levels
Within 1 day of the procedure, urine levels of KIM-1,
NGAL and IL-18 in patients in the intensive DCXC
therapy group were lower than those in the basic treat-
ment group and standard therapy group (P < 0.05) (Ta-
ble 3). There was no significant difference between the
standard therapy group and the basic treatment group
(P > 0.05).
Study end points
Overall, CIN occurred in 11 of 120 patients (Table 2).
The prevalence of CIN in the DCXC treatment groups
was lower compared with the basic treatment group
(P < 0.05), and a more significant decrease in the prev-
alence of CIN in the intensive DCXC therapy group
was shown (P < 0.01).
Compared with the basic treatment group, a lower pro-
portion of patients in the DCXC treatment groups had
an eGFR decrease of 25% or greater (P < 0.05); pa-
tients with an eGFR decrease of 25% or greater ac-
counted for an even lower proportion in the intensive
DCXC therapy group (P < 0.01).
Characteristics
Baseline Scr (μmol/L)
Day 1 after procedure (μmol/L)
Day 2 after procedure (μmol/L)
Day 3 after procedure (μmol/L)
Baseline eGFR (mL/min·1.73 m2)
Day 1 after procedure (mL/min·1.73m2)
Day 2 after procedure (mL/min·1.73m2)
Day 3 after procedure (mL/min·1.73m2)
eGFR > 25% decrease [n (%)]
Prevalence of CIN [n (%)]
Basic treatment
group (n = 41)
122±19
130±19a
137±20b
126±18
50±6
46±6a
40±6b
48±6
7 (17.07)
6 (14.63)
Standard DCXC therapy
group (n = 39)
121±19
129±18a
136±19b
126±17
50±6
47±7a
40±7b
49±6
4 (10.26) c
3 (7.69) c
Intensive DCXC
therapy group (n = 40)
122±19
127±19ac
130±19bce
124±17
52±6
50±6ac
44±7bce
50±6
3 (7.50) d
2 (5.00) d
Notes: basic treatment group was received aspirin (100 mg/d was administered indefinitely), clopidogrel (600 mg loading dose, followed
by 75 mg/d for at least 12 months), rosuvastatin (10 mg/d), metoprolol (23.75 mg/d), benazepril (10 mg/d), fondaparinux (2.5 mg/dfor at
least 5 days), furosemide (20 mg/d). Standard DCXC therapy group was treated with 2-g corbrin capsules, 3 times/day, 3 days before and
after angiography. Intensive DCXC therapy group was treated with 3-g corbrin capsules, 3 times/d, 3 days before and after angiography.
DCXC: Dongchongxiacao (Cordyceps); Scr: serum creatinine; eGFR: estimated glomerular filtration rate; CIN: contrast-induced nephropa-
thy. a P < 0.05, compared with baseline; b P < 0.01, compared with baseline; c P < 0.05, compared with basic treatment group; dP < 0.01,
compared with basic treatment group; eP < 0.05, compared with Standard DCXC therapy group.
Table 2 Changes in Scr and eGFR levels ( xˉ ± s)
A totle of 120 type 2 diabetics with eGFR ≤
60 mL/min·1.73m2 screened
Basic treatment group
(n = 41)
Standard DCXC therapy group
(n = 39)
Intensive DCXC therapy group
(n = 40)
Corbin capsule were used 3 days before and
after angiography
2 g, 3 times/d 3 g, times/d
Assess clinical and procedural characteristics, Serum creatinine, eGFR, urine
KIM-1, IL-18, NGAL levels
Statistical analyses
Figure 1 Flow chart of study
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DISCUSSION
CIN is a serious complication caused by radiological
imaging. The diagnosis of CIN often relies on a rela-
tive (≥ 25%) or an absolute (≥ 44.2 μmol/L) increase
in serum creatinine from the baseline value within 3
days after intravascular administration of contrast me-
dium.7 The occurrence of CIN remains a major con-
cern in patients with type 2 diabetes and moder-
ate-to-severe renal impairment defined as an eGFR <
60 mL/min·1.73 m2.8 Recent studies indicate that the
values of eGFR and urine KIM-1, NGAL and IL-18
can specifically predict the development and progres-
sion of CIN.9
It is widely recognized that medullary ischemia and oxi-
dant or free radical injury, resulting from renal vasocon-
striction, have major roles in the pathogenesis of
CIN.10 Many clinical observations have evaluated vari-
ous agents such as N-acetylcysteine, probucol, ascorbic
acid and statins in an effort to identify optimal strate-
gies to reduce the prevalence of CIN, but the results
are inconsistent.11,12
DCXC, which contains a variety of amino acids and in-
organic elements, can elevate the tolerance of the body
to anoxia and ameliorate poor microcirculation. Some
basic and clinical studies have proven its efficacy for
treating microcirculatory disorders. DCXC could im-
prove non-alcoholic fatty liver disease in mice by im-
proving microcirculation dysfunction, as reported by
Li et al.14 In recent years, DCXC has been used to pre-
vent contrast-induced renal impairment. In our previ-
ous study, prophylactic treatment with DCXC in sta-
ble angina pectoris patients undergoing coronary angi-
ography could prevent CIN. The mechanism is that
DCXC can reinforce the kidney, replenish Qi, and
strengthen essence. It can also correct obvious primary
deficiency syndrome.15 The glomerular blood flow in-
creases after administration of DCXC, which can ame-
liorate renal ischemia and attenuate the damage of re-
nal microvessels and tissue structure.16 DCXC pro-
motes renal blood flow by increasing plasma prosta-
glandin E2 level.17 The renal protective effects of
DCXC may be associated with activating super oxide
dismutase in renal tissues which can scavenge reactive
oxygen species and produce antioxidant effects.18
There has been little evidence regarding the effects of
traditional Chinese medicine on CIN thus far. There-
fore, we designed the present study to test the safety
and efficacy of DCXC on the prevalence of CIN. The
protocol of our study was similar to other studies
which aimed to investigate the short-term effects of
medical treatments on the prevalence of CIN.11 In the
present study, CIN occurred in 11 of 120 patients. The
prevalence of CIN in the DCXC treatment groups was
lower compared with the basic treatment group. We se-
lected Scr, eGFR and urine levels of KIM-1, NGAL
and IL-18 after the procedure as an index of renal func-
tion. Compared with the basic treatment group, a low-
er proportion of patients in the DCXC treatment
groups had an eGFR decrease of 25% or greater. After
the procedure, urine KIM-1, NGAL and IL-18 levels
in patients in the intensive DCXC therapy group were
lower than those in the basic treatment group and stan-
dard therapy group. Although renal function was only
monitored for three days after the procedure, a benefi-
cial effect of treatment with DCXC is highly probable.
These results strongly suggest the preventive effect of
short-term DCXC therapy on CIN in patients with
type 2 diabetes and renal insufficiency who are exposed
to contrast medium.
The present study has several limitations. First, the
study was only a single center study with a small sam-
ple size, which would have weakened the statistical
power of the conclusions. Second, CIN is the adverse
result of short-term influence imposed by contrast me-
dium on renal function. DCXC may also improve the
Table 3 Changes in urine KIM-1, NGAL and IL-18 levels ( xˉ ± s)
Characteristics
Baseline KIM-1 (ng/mL)
Day 1 after procedure KIM-1 (ng/mL)
Baseline NGAL (ng/mL)
Day 1 after procedure NGAL (ng/mL)
Baseline IL-18 (ng/L)
Day 1 after procedure IL-18 (ng/L)
Basic treatment group
(n = 41)
0.72±0.07
5.62±0.28a
7.98±4.02
66.52±10.73a
42.98±5.81
62.13±3.52a
Standard DCXC therapy
group (n = 39)
0.70±0.06
4.83±0.31a
7.62±3.76
57.12±9.68a
41.62±4.55
55.79±4.18a
Intensive DCXC therapy
group (n = 40)
0.71±0.05
2.76±0.32abc
7.79±3.91
41.65±8.41abc
40.34±4.98
46.79±4.32abc
Notes: basic treatment group was received aspirin (100 mg/d was administered indefinitely), clopidogrel (600 mg loading dose, followed
by 75 mg/d for at least 12 months), rosuvastatin (10 mg/d), metoprolol (23.75 mg/d), benazepril (10 mg/d), fondaparinux (2.5 mg/d for
at least 5 days), furosemide (20 mg/d). Standard DCXC therapy group was treated with 2-g corbrin capsules, 3 times/day, 3 days before
and after angiography. Intensive DCXC therapy group was treated with 3-g corbrin capsules, 3 times/day, 3 days before and after angiogra-
phy. DCXC: Dongchongxiacao (Cordyceps); KIM-1: kidney injury molecule-1; NGAL: urine neutrophil-gelatinase-associated-lipocalin;
IL-18: interleukin-18. a P < 0.05, compared with baseline; b P < 0.05, compared with basic treatment group; c P < 0.05, compared with
Standard DCXC therapy group.
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long-term prognosis of CIN, but in our study the pa-
tients were followed for only 3 days after contrast pro-
cedure. Some publications have stated that Scr peaked
at 3-5 days after administration of the contrast medi-
um and returned to normal within 10 days after. Thus,
this study may have missed some of the peak levels of
Scr. However, most patients who develop CIN usually
have increased creatinine within 3 days after contrast
administration, and hence most patients with CIN
would have been detected in the present study. Third,
the study results cannot be extended to patients with
severe kidney failure such as those with uremia. There-
fore, a large well-designed trial addressing the effect of
DCXC on long-term clinical outcomes is needed be-
fore this agent could be added to the armamentarium
in the prevention of CIN.
In conclusion, DCXC might be a protective factor
against the development of CIN in patients with type
2 diabetes and renal insufficiency undergoing coronary
angiography, with intensive DCXC therapy being
more effective.
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